IL Therapeutics Inc. was previously owned by Western Life Sciences Venture Fund LP ("Western Life Sciences") and in 2006 its shares were purchased by...
5 KB (342 words) - 15:34, 14 October 2021
Financial Financials Asset managers Winnipeg 1926 Asset management IL Therapeutics Health care Biotechnology Saskatoon 2005 Bio-tech IMAX Corporation...
86 KB (695 words) - 23:50, 27 July 2024
Plasma Resources Guardian Biotechnologies Great Western Brewing Company IL Therapeutics Prairie Plant Systems Robin Hood Flour Affinity Credit Union First...
2 KB (180 words) - 02:08, 5 October 2023
operations. In September 2022, Roche acquired Good Therapeutics at a cost of $250M for its PD1-regulated IL-2 receptor agonist program. In July 2023, Roche...
56 KB (5,124 words) - 17:16, 10 August 2024
Sotio (section IL-15 Superagonist)
Swiss NBE-Therapeutics on the development of novel antibody-drug conjugate products (ADC), with its affiliate Cytune Pharma on developing novel IL-15-based...
12 KB (1,170 words) - 16:33, 15 September 2023
Topokine Therapeutics (Acq 2016) Vitae Pharmaceuticals, Inc (Acq 2016) Tobira Therapeutics (Acq 2016) ForSight VISION5 (Acq 2016) RetroSense Therapeutics (Acq...
40 KB (3,359 words) - 06:40, 2 August 2024
proliferate CD8+ T cells and NK cells. It is being developed by Nektar Therapeutics. In August 2019 the FDA granted breakthrough therapy designation to bempegaldesleukin...
7 KB (599 words) - 00:43, 16 August 2023
org. Retrieved 2021-06-22. Therapeutics, Neoleukin (June 2020). "NL-201: A de novo CD25-independent combined IL-2 and IL-15 receptor agonistdesigned...
4 KB (388 words) - 23:01, 13 December 2023
Pluri Inc. (redirect from Pluristem Therapeutics)
Pluri Inc., formerly Pluristem Therapeutics, is an Israeli company engaged in the development of human placental adherent stromal cells for commercial...
24 KB (2,195 words) - 18:30, 17 June 2024
Anti-interleukin-6 (redirect from IL-6 inhibitor)
Anti-interleukin-6 agents are a class of therapeutics. Interleukin 6 is a cytokine relevant to many inflammatory diseases and many cancers. Hence, anti-IL6...
12 KB (1,289 words) - 19:20, 4 December 2023
Pharmaceuticals and its RNAi therapeutics, for $3.3 billion ($38.25 per share). In September 2022, Novo agreed to acquire Forma Therapeutics for $1.1 billion with...
38 KB (3,586 words) - 09:08, 9 August 2024
companies, these include Guardian Biotechnologies, Prairie Plant Systems, IL Therapeutics among others. Most major Canadian banks and financial services companies...
27 KB (2,989 words) - 02:16, 31 March 2024
factors such as TGF beta, VEGF, and PDGF Cytokines such as IL-1, IL-2, IL-4, IL-5, IL-6, IL-8, IL-9, IL-13, and TNF alpha There are also eosinophils that play...
28 KB (3,105 words) - 16:05, 11 July 2024
Lake Forest, Illinois (redirect from Lake Forest, IL)
Hospira are located in Lake Forest; Akorn, Covered Logistics, Horizon Therapeutics, IDEX, Packaging Corporation of America, Pactiv, Prestone, and Trustmark...
36 KB (3,449 words) - 15:44, 17 June 2024
December 2014). "Treatment of adult-onset Still's disease: a review". Therapeutics and Clinical Risk Management. 11: 33–43. doi:10.2147/TCRM.S64951. PMC 4278737...
17 KB (1,754 words) - 21:29, 9 July 2024
"Diuretics: a review and update". Journal of Cardiovascular Pharmacology and Therapeutics. 19 (1): 5–13. doi:10.1177/1074248413497257. PMID 24243991. S2CID 21204143...
37 KB (3,650 words) - 17:39, 27 July 2024
which include IL-2, IL-4, IL-6, IL-13, and IL-31 (TSLP, another pruritogenic cytokine that uses JAKs, has also been found to be inhibited). IL-31 is a key...
16 KB (1,412 words) - 06:19, 26 June 2024
(2016). "Secukinumab for ankylosing spondylitis and psoriatic arthritis". Therapeutics and Clinical Risk Management. 12: 1587–1592. doi:10.2147/TCRM.S100091...
15 KB (1,153 words) - 05:27, 18 July 2024
Janssen Pharmaceuticals (redirect from Janssen Therapeutics)
novel antibody treatment (bermekimab) that neutralizes interleukin-1 alpha (IL-1⍺) to Janssen Biotech, Inc. On 27 March 2020, the U.S. Biomedical Advanced...
33 KB (3,155 words) - 19:07, 9 August 2024
Hyper-IL-6 is a designer cytokine, which was generated by the German biochemist Stefan Rose-John. Hyper-IL-6 is a fusion protein of the four-helical cytokine...
14 KB (1,664 words) - 11:41, 8 February 2024
intravenously in postaddicts". The Journal of Pharmacology and Experimental Therapeutics. 133: 388–99. PMID 13767429. National Institute on Drug Abuse (NIDA)...
140 KB (13,709 words) - 18:15, 16 August 2024
non-erosive gastro-oesophageal reflux disease". Alimentary Pharmacology & Therapeutics. 21 (Suppl 2): 10–8. doi:10.1111/j.1365-2036.2005.02468.x. PMID 15943841...
27 KB (2,342 words) - 03:27, 8 August 2024
Monoclonal antibody therapy (redirect from Antibody therapeutics)
Hong K, Benz CC (2000). "Emerging antibody-based HER2 (ErbB-2/neu) therapeutics". Breast Disease. 11: 113–124. doi:10.3233/bd-1999-11110. PMID 15687597...
57 KB (4,072 words) - 11:12, 5 August 2024
receptor. the interferon (IFN) subfamily. the IL-10 subfamily. The IL-1 family, which primarily includes IL-1 and IL-18. The cysteine knot cytokines (IPR029034)...
35 KB (3,892 words) - 12:38, 3 August 2024
March 2019. "[99] Comparative effectiveness of proton pump inhibitors | Therapeutics Initiative". 28 June 2016. Retrieved 14 July 2016. "Dexlansoprazole Use...
8 KB (701 words) - 05:22, 10 June 2024
gene expression of cytokines including Interleukin 1 (IL-1), IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, and TNF-alpha by binding to corticosteroid response...
29 KB (3,337 words) - 00:02, 9 August 2024
Autocrine signaling (section IL-6)
"low-affinity" IL-2 receptors are replaced by "high-affinity" IL-2 receptors consisting of α, β, and γ chains. The cell then releases IL-2, which binds...
18 KB (2,105 words) - 17:15, 1 December 2023
increases plasma concentrations of buspirone". Clinical Pharmacology and Therapeutics. 64 (6): 655–660. doi:10.1016/S0009-9236(98)90056-X. PMID 9871430. S2CID 22009095...
42 KB (3,631 words) - 13:44, 27 July 2024
Magrathea Marble Therapeutics Matter Mistral AI MultiplyLabs N5 Now Nebuly Neumora Neuralink Newcleo Norbert Health Orbital Therapeutics Osmo PhaseV Q Qonto...
57 KB (5,109 words) - 00:41, 15 August 2024
IRAK4 (redirect from Il-1R–Associated Kinase 4 Deficiency)
have recently entered clinical trials, most notably one from Kymera Therapeutics. Emavusertib (CA-4948) Zimlovisertib (PF-06650833) GRCh38: Ensembl release...
20 KB (2,536 words) - 18:01, 13 August 2024